Physician profile
Willie Y Chen
NPI 1144216631
$8,864.54
in general payments reported to CMS, 2019-2025
29 companies · $1,663 in 2025
The $1,663 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $823 · 2021: $1,172 · 2022: $1,320 · 2023: $1,476 · 2024: $1,167 · 2025: $1,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,184 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,183.63 |
| Education | $123.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,382.58 | 2019-2025 | Cequa |
| Alcon Vision LLC | $835.47 | 2019-2025 | Rocklatan, Rhopressa, Tryptyr |
| Mallinckrodt Hospital Products INC. | $803.47 | 2021-2025 | Acthar |
| Kala Pharmaceuticals, INC. | $568.96 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $559.55 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Abbvie INC. | $552.58 | 2022-2025 | Alphagan P, Vuity, Lumigan |
| Allergan, INC. | $522.64 | 2019-2022 | |
| Sight Sciences, INC. | $423.69 | 2019-2025 | Tearcare System, Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $412.54 | 2019-2025 | Idose |
| Oyster Point Pharma, INC. | $407.97 | 2022-2025 | Tyrvaya |
| Harrow Eye, LLC | $311.70 | 2024-2025 | Vevye |
| Eyepoint US, INC. | $250.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $234.61 | 2019-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $218.04 | 2019-2025 | Tecnis Iol, Tecnis Simplicity |
| Dompe US, INC. | $207.70 | 2022-2025 | Oxervate |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $181.21 | 2022-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Biotissue Holdings INC. | $165.17 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $163.53 | 2019-2021 | |
| Ivantis, INC | $160.64 | 2021 | |
| Alimera Sciences, INC. | $127.49 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $127.15 | 2024-2025 | Xdemvy |
| Shire North American Group INC | $80.98 | 2019 | |
| Aerie Pharmaceuticals, INC. | $55.29 | 2021 | |
| Ocular Therapeutix, INC. | $35.05 | 2019 | |
| Akorn Operating Company LLC | $22.46 | 2021 | |
| Rayner Intraocular Lenses Limited | $18.94 | 2023 | Omidria, Rayone Emv, Rayone Aspheric |
| Mallinckrodt Enterprises LLC | $18.20 | 2019 | |
| Thea Pharma INC. | $16.93 | 2023 | Iyuzeh |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willie Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.